Truist Securities Maintains Buy on Inspire Medical Systems, Raises Price Target to $280
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Buy rating on Inspire Medical Systems (INSP) and raises the price target from $265 to $280.
February 07, 2024 | 9:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Richard Newitter maintains a Buy rating on Inspire Medical Systems and raises the price target from $265 to $280.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100